Tubulin interacting agents: Novel taxanes and epothilones

Current Oncology Reports

Volumn 5, Issue 2, 2003, Pages 89-98

  Agrawal, Neeraj R ^a   Ganapathi, Ram ^a   Mekhail, Tarek ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIARRHYTHMIC AGENT; ANTINEOPLASTIC AGENT; BMS 184476; BMS 188797; BMS 275183; BMS 310705; CALCIUM CHANNEL BLOCKING AGENT; CARBOPLATIN; COLCHICINE DERIVATIVE; CREMOPHOR; CYCLOSPORIN A; DISCODERMOLIDE; DOCETAXEL; EPOTHILONE A; EPOTHILONE B; ETOPOSIDE; GLYCOPROTEIN P; IXABEPILONE; LAULIMALIDE; MAC 321; MACROGOL; MULTIDRUG RESISTANCE PROTEIN 1; ORTATAXEL; PACLITAXEL; RPR 109881A; TAMOXIFEN; TAXANE DERIVATIVE; TAXOPREXIN; TL 139; UNCLASSIFIED DRUG; UNINDEXED DRUG; BRIDGED COMPOUND; EPOTHILONE DERIVATIVE; TAXANE; TAXOID; TUBULIN;

ALOPECIA; ANOREXIA; APOPTOSIS; ARTHRALGIA; BONE MARROW SUPPRESSION; BREAST CANCER; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CLINICAL TRIAL; COLON CARCINOMA; CONSTIPATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HUMAN; HYPONATREMIA; INFECTION; KERATITIS; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LEUKOPENIA; LUNG CANCER; MAXIMUM TOLERATED DOSE; MELANOMA; MICROTUBULE; MITOSIS; MUCOSA INFLAMMATION; MYALGIA; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; OVARY CARCINOMA; PAIN; PANCREAS ADENOCARCINOMA; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PROTEIN POLYMERIZATION; REVIEW; STOMATITIS; URINE RETENTION; VOMITING; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG RESISTANCE; METHODOLOGY; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BRIDGED COMPOUNDS; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; HUMANS; PACLITAXEL; TAXOIDS; TUBULIN;

EID: 0642377750     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-003-0095-6     Document Type: Review

References (65)

1. Palmer CG, Livengood D, Warren AK, et al.: The action of vincaleukoblastine on mitosis in vitro. Exp Cell Res 1960, 20:198-265.
2. Wani MC, Taylor HL, Wall ME, et al.: Plant antitumor agents. VI. The isolation and structure of paclitaxel, a novel anti-leukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971, 93:2325-2327.
3. Cortes JE, Pazdur R: Docetaxel. J Clin Oncol 1995, 13:2643-2655.
4. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by Taxol. Nature 1979, 277:665-667.
5. Rowinsky EK, Donehower RC: Drug therapy: paclitaxel (Taxol). N Engl J Med 1995, 332:1004-1014.
6. Tishler RB, Schiff PB, Geard CR, et al.: Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992, 22:613-617.
7. Jordan MA, Wendell K, Gardiner S, et al.: Mitotic block induced in HeLa cells by low paclitaxel (Taxol) results in abnormal mitotic cell death. Cancer Res 1996, 56:816-825.
8. Di Leonardo A, Khan SH, Linke SP, et al.: DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res 1997, 57:1013-1019.
9. Woods CM, Zhu J, McQueney PA, et al.: Taxol induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1995, 1:506-526.
10. Poruchynsky MS, Wang EE, Rudin CM, et al.: Bcl-xL is phosphorylated in malignant cells following microtubule disruption. Cancer Res 1998, 58:3331-3338.
11. Wang LG, Liu XM, Kreis W, et al.: The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 1999, 44:355-361.
12. Dumontet C, Sikic BI: Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999, 17:1061-1070.
13. Bhalla K, Ibrado AM, Tourkina E, et al.: Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 1993, 7:563-568.
14. Burkhart CA, Berman JW, Swindell CS, et al.: Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor-alpha gene expression and cytotoxicity. Cancer Res 1994, 5:5779-5782.
15. Cabral F, Wible L, Brenner S, Brinkley BR: Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly. J Cell Biol 1983, 97:30-39.
16. Dumontet C: Mechanisms of action and resistance to tubulin-binding agents. Expert Opin Investig Drugs 2000, 9:779-788.
17. Monzo M, Rossell R, Sanchez JJ, et al.: Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 1999, 17:1786-1793.
18. Horwitz SB, Cohen D, Rao S, et al.: Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 1993, 15:55-61.
19. Woodcock DM, Jefferson S, Linsenmeyer ME, et al.: Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 1990, 50:199-203.
20. Webster L, Linsenmeyer M, Millward M, et al.: Measurement of cremophor EL following Taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J Natl Cancer Inst 1993, 85:1685-1690.
21. McDaid HM, Bhattacharya SK, Chen XT, et al.: Structure-activity profiles of eleutherobin analogs and their crossresistance in Taxol-resistant cell lines. Cancer Chemother Pharmacol 1999, 44:131-137.
22. Lavelle F: New taxanes and epothilone derivatives in clinical trials. Bulletin du Cancer 2002, 89:343-350.
23. William C, Lee FY, Fairchild CR, et al.: Preclinical antitumor activity of a new paclitaxel analog, BMS-184476. Proceedings of the NCI-EORTC Symposium on New Drugs in Cancer Therapy 2000, 11:552.
24. Kim JS, Amorino GP, Pyo H, et al.: The novel taxane analogs, BMS-184476 and BMS-188797, potentiate the effects of radiation therapy in vitro and in vivo against human lung cancer cells. Int J Radiat Oncol Biol Physics 2001, 51:525-534.
25. Plummer R, Ghielmini M, Calvert P, et al.: Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies. Clin Cancer Res 2002, 8:2788-2797.
26. Advani R, Fisher GA, Jambalos C, et al.: Phase I study of BMS-188797, a new taxane analog administered weekly in patients with advanced malignancies [abstract]. Proc ASCO 2001, 20:422.
27. Gelmon KA, Latreille J, Tolcher A, et al.: Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. J Clin Oncol 2000, 18:4098-4108.
28. Wolff A, Baker S, Bowling M, et al.: Phase I study of taxoprexin DHA-paclitaxel (Txp), a novel taxane with unique preclinical activity, pharmacology, and toxicity profile [abstract]. Proc ASCO 2000, 19:921E.
29. Nuijen B, Bouma M, Schellens JHM et al.: Progress in the development of alternative pharmaceutical formulations of taxanes. Investig New Drugs 2001, 19:143-153.
30. Bowden C, Huang C, Eisenberg P, et al.: Phase 1 trial in advanced malignancies with liposome encapsulated paclitaxel (LEP) Q 3 weeks [abstract]. Proc ASCO 2002, 21:1862.
31. Sabbatini P, Brown J, Aghajanian C, et al.: A phase I/II study of PG-paclitaxel (CT-2103) in patients (patients) with recurrent ovarian, fallopian tube, or peritoneal cancer [abstract]. Proc ASCO 2002, 21:871.
32. Harper H, Marsland T, Mitchell P, et al.: Phase II study of first line chemotherapy using CT-2103 in patients with non-small-cell lung cancer who are greater than 70 years of age or who have PS of 2 years [abstract]. Proc ASCO 2002, 21:2685.
33. Ibrahim N, Ellerhorst J, Theriault R, et al.: Phase I study of cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel (Abi-007) in solid tumors [abstract]. Proc ASCO 2000, 19:609F.
34. Campbell KJ, Hersh EM, Stopeck A, et al.: A phase I trial of ABI-007 administered weekly for three doses every 4 weeks in patients with advanced non-hematologic malignancies [abstract]. Proc ASCO 2002, 21:403.
35. Eiseman JL, Eddington ND, Leslie J, et al.: Plasma pharmocokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol 1994, 34:465-471.
36. Trump DL, Egorin MJ, Ramesh R, et al.: A new oral taxane (BMS-275183): phase I trial with evaluation of pharmacokinetics, pharmacodynamics and bioavailability [abstract]. Proc ASCO 2002, 21:398.
37. Hofle G, Bedorf N, Seinmetz H, et al.: Epothilone A and B-novel 16-membered macrolides with cytotoxic activity: isolation, crystal structure, and conformation in solution [in English]. Angewandte Chemie International Edition 1996, 35:1567-1569.
38. Cowden CJ, Paterson I: Synthetic chemistry: cancer drugs better than Taxol? Nature 1997, 387:238-239.
39. Bollag DM, McQueney PA, Zhu J, et al.: Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995, 55:2325-2333.
40. Giannakakou P, Gussio R, Nogales E, et al.: A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A 2000, 97:2904-2909.
41. Bode CJ, Gupta ML Jr, Reiff EA, et al.: Unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry 2002, 41:3870-3874.
42. Muhlradt PF, Sasse F: Epothilone B stabilizes microtubuli of macrophages like Taxol without showing Taxol-like endotoxin activity. Cancer Res 1997, 57:3344-3346.
43. Mani S, McDaid H, Shen H, et al.: Phase I pharmacokinetic and pharmacodynamic study of an epothilone B analog (BMS-247550) administered as a 1-hour infusion every 3 weeks: an update [abstract]. Proc ASCO 2002, 21:409.
44. Kowalski RJ, Giannakakou P, Hamel E: Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J Biol Chem 1997, 272:2534-2541.
45. Lee FY, Borzilleri R, Fairchild CR, et al.: BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001, 7:1429-1437.
46. Yamaguchi H, Paranawithana SR, Lee MW, et al.: Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer Res 2002, 62:466-471.
47. Guo F, Nimmanapalli R, Paranawithana S, et al.: Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood 2002, 99:3419-3426.
48. Tripathi R, Gadgeel SM, Wozniak AJ, et al.: Phase I clinical trial of BMS-247550 (epothilone B derivative) in adult patients with advanced solid tumors [abstract]. Proc ASCO 2002, 21:407.
49. Okuno S, Geyer SM, Maples WJ, et al.: Phase 2 study of epothilone B analog (BMS-247550) in soft tissue sarcomas: an interim report [abstract]. Proc ASCO 2002, 21:1645.
50. Burris HA III, Awada A, Jones S, et al.: Phase I study of the novel epothilone BMS-247550 administered weekly in patients with advanced malignancies [abstract]. Proc ASCO 2002, 21:412.
51. Awada A, Jones S, Piccart M, et al.: Final results of the phase I study of the novel epothilone BMS-247550 administered weekly in patients (pts) with advanced solid tumors [abstract]. Eur J Cancer 2002, 38:41.
52. Hao D, Hammond LA, deBono JS, et al.: Continuous weekly administration of the epothilone-B derivative, BMS247,550 (NSC710428): a phase I and pharmacokinetic (PK) study [abstract]. Proc ASCO 2002, 21:411.
53. Agrawal M, Kotz H, Abraham J, et al.: A phase I clinical trial of BMS 247550 (NSC 71028), an epothilone B derivative, in patients with refractory neoplasms [abstract]. Proc ASCO 2002, 21:410.
54. McDaid HM, Mani S, Shen HJ, et al.: Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res 2002, 8:2035-2043.
55. Damle B, Letrent S, Duncan G, et al.: Pharmacokinetics (PK) and pharmacodynamics (PD) of BMS-247550, an epothilone analog, in patients with advanced solid tumors [abstract]. Proc ASCO 2001, 20:268.
56. Plummer R, Molife R, Verrill M, et al.: Phase I and pharmacokinetic study of BMS-247550 in combination with carboplatin. Eur J Cancer 2002, 38:42.
57. Delbaldo C, Lara PN, Vansteenkiste J, et al.: Phase II study of the novel epothilone BMS-247550 in patients (pts) with recurrent or metastatic non-small cell lung cancer (NSCLC) who have failed first-line platinum-based chemotherapy [abstract]. Proc ASCO 2002, 21:1211.
58. Ajani J, Shah MA, Bokemeyer C, et al.: Phase II study of the novel epothilone BMS-247550 in patients (pts) with metastatic gastric adenocarcinoma previously treated with a taxane [abstract]. Proc ASCO 2002, 21:619.
59. Smaletz O, Kelly WK, Horse-Grant D, et al.: Epothilone B analogue (BMS-247550) with estramustine phosphate (EMP) in patients (pts) with progressive castrate-metastatic prostate cancer (PC) [abstract]. Proc ASCO 2002, 21:732.
60. Mekhail T, Takigawa N, Lee F, et al.: Apoptotic pathways and novel activity of the epothilone B analog bms-310705 in human non-small cell lung carcinoma (NSCLC) [abstract]. Eur J Cancer 2002, 38:40.
61. Uyar D, Takigawa N, Kennedy A, et al.: Characterization of cell death mechanisms of BMS 310705, an epothilone derivative [abstract]. Proc Amer Assoc Cancer Res 2002, 43:922.
62. Broker LE, Huisman C, Ferreira CG, et al.: Late activation of apoptotic pathways plays a negligible role in mediating the cytotoxic effects of discodermolide and epothilone B in non-small cell lung cancer cells. Cancer Res 2002, 62:4081-4088.
63. Mekhail T, Holden S, Pierson S, et al.: A phase I pharmacokinetic and biologic study of the novel epothilone BMS-310705 in patients with advanced cancer [abstract]. Proc ASCO 2002, 21:408.
64. Calvert PM, O'Neill V, Twelves C, et al.: A phase I clinical and pharmacokinetic study of EPO906 (epothilone B), given every three weeks, in patients with advanced solid tumors [abstract]. Proc ASCO 2001, 20:429.
65. Rosen P, Rosen LS, Britten C, et al.: KOS-862 (epothilone D): results of a phase I dose-escalating trial in patients with advanced malignancies [abstract]. Proc ASCO 2002, 21:413.